Pular para o conteúdo
· Preenchimentos dérmicos
SKU 10368

Ellansé S

Em stock
Volume
2 x 1 mL
Laboratório
Sinclair Pharma
Origem
Países Baixos
Indicação
Facial volume loss and contour correction
O preço profissional e o histórico são exclusivos de contas verificadas
allpara fornece profissionais licenciados. Inicie sessão ou peça uma conta B2B para ver os preços em tempo real, os escalões por volume e o histórico de preços.

Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, intended for subdermal implantation in the face to correct wrinkles and facial ageing signs or conditions in a lasting way. It is recommended for minimal volume augmentation and offers 18 months of longevity against 24 months for Ellansé M, a difference due to the shorter PCL chain length of its microspheres. The implant combines 30% synthetic Poly-e-caprolactone (PCL) microspheres with a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC); the gel immediately fills areas of volume loss and is resorbed 2 to 3 months after injection, after which the microspheres are progressively replaced by the patient's own collagen, predominantly type I, reshaping facial contours over time. Ellansé S comes as 2 x 1 mL ready-to-use syringes with four 27G needles and is a Class III medical device, CE marked since 2009 under Medical Device Directive 93/42/EEC.

Principais vantagens de Ellansé S

  • Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
  • Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
  • 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of 25 to 50 microns
  • 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
  • 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
  • The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
  • Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
  • Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
  • Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
  • Class III medical device, CE marked since 2009
Informação essencial
Marca ELLANSÉ
Fabricante Sinclair Pharma
País de origem Netherlands
Certificação CE marked since 2009. Class III medical device under Medical Device Directive 93/42/EEC, Annex IX, Rule 8. GMDN 61219. Basic UDI-DI 50600330427180950212191JR
Composição Synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline (PBS), glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier. PCL microsphere diameter 25 to 50 microns. Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
Volume / Tamanho 1 ml
Embalagem 2 x 1 mL ready-to-use syringes, with four 27G needles included
Tamanho da agulha Four 27G needles supplied in the pack, purchased as CE marked devices
Tipo de utilização For professional use - qualified practitioners and clinics only
Profundidade de injeção Subdermal implantation in the face, into the subcutaneous fat or hypodermis. Injection modalities are recommended per facial region (upper, mid and lower face) and per area, and depend on the depth of implantation and the desired degree of volume correction
Protocolo / Duração 18 months of longevity, against 24 months for Ellanse M. The two options are distinguished only by the initial polymer chain length of the PCL, with the shorter chains in the S variant degrading sooner. Treatment effects vary with the variant used, the practitioner's injection technique, and patient lifestyle and metabolic rate

Indicações e utilização profissional

Principais indicações

  • Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
  • Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
  • Minimal volume augmentation, which is the position of Ellanse S within the range

Utilização profissional

This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.

Zonas de tratamento

  • Upper face: forehead, temples, brow area
  • Mid face: nose reshaping, cheek augmentation, nasolabial folds
  • Lower face: oral commissures, marionette lines, chin definition, jawline
  • Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area

Perfil do paciente

Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation.

Como funciona Ellansé S ​

Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, 25 to 50 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill. Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.

Porquê encomendar na Allpara

A Allpara oferece produtos ELLANSÉ originais e verificados de fornecedores selecionados, com rastreabilidade total dos lotes e apoio especializado. Servimos clínicas e profissionais de estética com produtos com certificação CE, entrega rápida em toda a UE a partir do nosso armazém na UE e preços profissionais competitivos. A nossa prioridade é a segurança, a satisfação e os resultados dos seus pacientes, com apoio pós-venda dedicado para a sua tranquilidade.

Perguntas frequentes

Ellanse S vs M: which should a clinic stock?

Both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for S and 24 months for M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.

How long does Ellansé S last?

Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.

What is Ellansé S made of?

Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, 25 to 50 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.

Mais de Sinclair

Ver laboratório

Alternativas para a clínica

Todos os produtos

Ellansé S

Em stock
Marcação CE Marcação CE Ellansé S
Preços exclusivos para contas verificadas
Inicie sessão ou peça uma conta B2B para ver o seu preço.
Pedir conta B2B

Ellansé S is a sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent injectable implant, intended for subdermal implantation in the face to correct wrinkles and facial ageing signs or conditions in a lasting way. It is recommended for minimal volume augmentation and offers 18 months of longevity against 24 months for Ellansé M, a difference due to the shorter PCL chain length of its microspheres. The implant combines 30% synthetic Poly-e-caprolactone (PCL) microspheres with a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose (CMC); the gel immediately fills areas of volume loss and is resorbed 2 to 3 months after injection, after which the microspheres are progressively replaced by the patient's own collagen, predominantly type I, reshaping facial contours over time. Ellansé S comes as 2 x 1 mL ready-to-use syringes with four 27G needles and is a Class III medical device, CE marked since 2009 under Medical Device Directive 93/42/EEC.

Principais vantagens de Ellansé S

  • Immediate volumising effect from the carboxymethylcellulose carrier gel, which fills areas affected by volume loss and is resorbed 2 to 3 months after injection
  • Progressive stimulation of the patient's own collagen, predominantly type I, by the polycaprolactone microspheres
  • 30% PCL microspheres to 70% CMC-based carrier gel, with a microsphere diameter of 25 to 50 microns
  • 18 months of longevity, against 24 months for Ellanse M, the two being distinguished only by the initial polymer chain length of the PCL
  • 90% of patients treated with Ellanse S or M had improved, much improved or very much improved results at 12 months
  • The intended option for more conservative, minimal volume augmentation within the Ellanse family, which makes it a reasonable starting point for a patient new to collagen stimulators
  • Treats upper, mid and lower face: forehead, temples, brow, nose, cheeks, nasolabial folds, oral commissures, marionette lines, chin and jawline
  • Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
  • Supplied as 2 x 1 mL ready-to-use syringes with four 27G needles
  • Class III medical device, CE marked since 2009
Informação essencial
Marca ELLANSÉ
Fabricante Sinclair Pharma
País de origem Netherlands
Certificação CE marked since 2009. Class III medical device under Medical Device Directive 93/42/EEC, Annex IX, Rule 8. GMDN 61219. Basic UDI-DI 50600330427180950212191JR
Composição Synthetic Poly-e-caprolactone (PCL) microspheres suspended in a carrier gel of phosphate buffered saline (PBS), glycerin and carboxymethylcellulose (CMC), in a ratio of 30% PCL microspheres to 70% gel carrier. PCL microsphere diameter 25 to 50 microns. Sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent
Volume / Tamanho 1 ml
Embalagem 2 x 1 mL ready-to-use syringes, with four 27G needles included
Tamanho da agulha Four 27G needles supplied in the pack, purchased as CE marked devices
Tipo de utilização For professional use - qualified practitioners and clinics only
Profundidade de injeção Subdermal implantation in the face, into the subcutaneous fat or hypodermis. Injection modalities are recommended per facial region (upper, mid and lower face) and per area, and depend on the depth of implantation and the desired degree of volume correction
Protocolo / Duração 18 months of longevity, against 24 months for Ellanse M. The two options are distinguished only by the initial polymer chain length of the PCL, with the shorter chains in the S variant degrading sooner. Treatment effects vary with the variant used, the practitioner's injection technique, and patient lifestyle and metabolic rate

Indicações e utilização profissional

Principais indicações

  • Subdermal implantation in the face for the lasting correction of wrinkles and facial ageing signs or conditions
  • Correction of age-related volume loss due to increased skin laxity, fat loss and diminished support from underlying muscle and bone
  • Minimal volume augmentation, which is the position of Ellanse S within the range

Utilização profissional

This product is supplied for administration by qualified medical practitioners only, within the scope of their professional registration and local regulations for injectable medical devices. It is a stand-alone device and is not required to be used in combination with any other device to meet its intended purpose. Injection technique, plane and volume are determined by the treating practitioner on a per-patient basis, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Selection between Ellanse S and Ellanse M is a decision about the degree of correction and the longevity required, and the two must not be treated as interchangeable. Each unit is sterile and for single use only.

Zonas de tratamento

  • Upper face: forehead, temples, brow area
  • Mid face: nose reshaping, cheek augmentation, nasolabial folds
  • Lower face: oral commissures, marionette lines, chin definition, jawline
  • Injected subdermally, into the subcutaneous fat or hypodermis, with modalities recommended per facial region and per area

Perfil do paciente

Intended for adult patients over 18 who are not pregnant or breast-feeding and who are deemed appropriate for treatment by the physician. Because polycaprolactone is a bioresorbable implant rather than a hyaluronic acid gel, patient selection and expectation setting carry additional weight and are determined by the practitioner at consultation.

Como funciona Ellansé S ​

Ellansé S works through two components. The carboxymethylcellulose gel provides immediate filling of areas affected by volume loss and is resorbed 2 to 3 months after injection. The polycaprolactone microspheres, 25 to 50 microns in diameter, are then progressively replaced by the patient's own collagen, predominantly type I, which rebuilds facial support and contour over time and produces the progressive refinement seen after the initial fill. Implantation is subdermal, with the approach depending on the facial region, the depth of implantation and the desired degree of volume correction. Within the range, Ellanse S is recommended for minimal volume augmentation while Ellanse M is intended for more extensive augmentation, so the two are not interchangeable on volume any more than on longevity. S lasts 18 months against 24 months for M, and that difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres: the shorter chains in the S variant degrade sooner.

Porquê encomendar na Allpara

A Allpara oferece produtos ELLANSÉ originais e verificados, com rastreabilidade total dos lotes, stock com certificação CE, entrega rápida em toda a UE e apoio pós-venda especializado.

Perguntas frequentes

Ellanse S vs M: which should a clinic stock?

Both are the same polycaprolactone collagen stimulator platform, supplied at different longevities: 18 months for S and 24 months for M. The difference comes from the chain length, or molecular weight, of the PCL chains within the microspheres, with the shorter chains in S degrading sooner. S is positioned for minimal volume augmentation and M for more extensive augmentation. Both are supplied as 2 x 1 mL, so clinics commonly hold both and match the variant to the patient.

How long does Ellansé S last?

Ellansé S offers 18 months of longevity. Duration varies with the individual patient, the area addressed, the volume placed and the injection technique used.

What is Ellansé S made of?

Ellansé S is 30% synthetic Poly-e-caprolactone microspheres, 25 to 50 microns in diameter, suspended in a 70% carrier gel of phosphate buffered saline, glycerin and carboxymethylcellulose. It is sterile, single use, latex-free, non-pyrogenic, bioresorbable and non-permanent. The carrier gel is resorbed 2 to 3 months after injection and is progressively replaced by the patient's own collagen, predominantly type I.

Mais de Sinclair

Ver o laboratório →
* Produto de uso profissional. A embalagem pode variar consoante o lote ou o mercado. Consulte as instruções de utilização fornecidas para as indicações completas e as contraindicações.